The organization has more than 500 technologies in development and oversees over 1,100 patents, focusing on biotech, medtech and digital health solutions advancing precision medicine.
“The idea is to identify all innovations and inventions from within our medical center and support the path to commercialize them domestically and globally,” said James Laur, chief intellectual property officer at Cedars-Sinai, in an April 16 news release.
A particularly successful Cedars-Sinai Technology Ventures spinoff is Prometheus Biosciences, the developer of a new therapeutic to treat inflammatory bowel disease. The health system’s venture fund had invested $40 million in the company, which was sold last June to Merck for nearly $11 billion, an estimated $800 million of which came back to Cedars-Sinai.
“It was the first such success at this scale seen in technology transfer offices around the world and validated our unique approach to bring new inventions to the market,” stated Nirdesh Gupta, PhD, managing director of Cedars-Sinai Technology Ventures and the Cedars-Sinai Accelerator.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.